BACKGROUND AND PURPOSE: We compare our institutional outcomes of synchronous primary (SP) lung lesion patients with non-SP patients.Materials and Methods: From an IRB approved prospective registry of 445 NSCLC patients treated with SBRT (8/2005 8/2012), 26 (5.8%) had SPs by biopsy or PET/CT. SBRT was delivered on a Novalis/BrainLAB platform with daily Exactrac set-up. RESULTS: There were no significant differences comparing SP vs non-SP groups for age, Charlson score, smoking pack years, and PET SUV (p=ns). 18 (69%) SP patients had at least one lesion biopsied. Ipsilateral and bilateral SPs were seen in 10 (38.4%) and 16 (61.6%) respectively. 77% received 50 Gy / 5 fx. SP vs non-SP median follow up was 12 (range 1.5-49.8) vs 15.2 months. Median survival for SP vs non-SP groups was 20.7 vs 28.4 months (p=0.3). In SP vs non-SP groups, local failure was 4% vs 7.6% (p=ns) and nodal/distant failure was 23% vs 24.6% (p=ns). Patients with ipsilateral and bilateral SPs had a 50% vs 14% distant failure respectively (p=0.037). CONCLUSIONS: After SBRT, there were no differences in survival and patterns of failure for SP vs non-SP patients. Ipsilateral SPs had significantly worse distant failure compared to bilateral SPs.
BACKGROUND AND PURPOSE: We compare our institutional outcomes of synchronous primary (SP) lung lesion patients with non-SP patients.Materials and Methods: From an IRB approved prospective registry of 445 NSCLC patients treated with SBRT (8/2005 8/2012), 26 (5.8%) had SPs by biopsy or PET/CT. SBRT was delivered on a Novalis/BrainLAB platform with daily Exactrac set-up. RESULTS: There were no significant differences comparing SP vs non-SP groups for age, Charlson score, smoking pack years, and PET SUV (p=ns). 18 (69%) SP patients had at least one lesion biopsied. Ipsilateral and bilateral SPs were seen in 10 (38.4%) and 16 (61.6%) respectively. 77% received 50 Gy / 5 fx. SP vs non-SP median follow up was 12 (range 1.5-49.8) vs 15.2 months. Median survival for SP vs non-SP groups was 20.7 vs 28.4 months (p=0.3). In SP vs non-SP groups, local failure was 4% vs 7.6% (p=ns) and nodal/distant failure was 23% vs 24.6% (p=ns). Patients with ipsilateral and bilateral SPs had a 50% vs 14% distant failure respectively (p=0.037). CONCLUSIONS: After SBRT, there were no differences in survival and patterns of failure for SP vs non-SP patients. Ipsilateral SPs had significantly worse distant failure compared to bilateral SPs.
Authors: Bernadette G Dijkman; Olga C J Schuurbiers; Dennis Vriens; Monika Looijen-Salamon; Johan Bussink; Johanna N H Timmer-Bonte; Miranda M Snoeren; Wim J G Oyen; Henricus F M van der Heijden; Lioe-Fee de Geus-Oei Journal: Eur J Nucl Med Mol Imaging Date: 2010-06-10 Impact factor: 9.236
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Gwendolyn H M J Griffioen; Frank J Lagerwaard; Cornelis J A Haasbeek; Egbert F Smit; Ben J Slotman; Suresh Senan Journal: Radiother Oncol Date: 2013-06-06 Impact factor: 6.280
Authors: David J Hoopes; Mark Tann; James W Fletcher; Jeffrey A Forquer; Pei-Fen Lin; Simon S Lo; Robert D Timmerman; Ronald C McGarry Journal: Lung Cancer Date: 2007-03-13 Impact factor: 5.705
Authors: Gregory M M Videtic; Kevin Stephans; Chandana Reddy; Stephen Gajdos; Matthew Kolar; Edward Clouser; Toufik Djemil Journal: Int J Radiat Oncol Biol Phys Date: 2009-09-18 Impact factor: 7.038